Business
NetworkNewsWire Announces Publication Discussing Unique R&D in the Medicinal Marijuana Industry
New York, New York--(Newsfile Corp. - October 30, 2017) - NetworkNewsWire ("NNW"), a multi...
About this update from Infield Minerals Corp
[{"type":"text","content":"NetworkNewsWire Announces Publication Discussing Unique R&D in the Medicinal Marijuana IndustryNew York, New York--(Newsfile Corp. - October 30, 2017) - NetworkNewsWire (\"NNW\"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.The publication, titled, \"Innovative Biotechnology Companies are Transforming Cannabis-based Medical Products,\" highlights biotech companies taking advantage of widespread interest and acceptance of the potential for cannabis-based products to treat a range of medical disorders.To view the full publication, visit: https://www.networknewswire.com/innovative-biotechnology-companies-transforming-cannabis-based-medical-products/ \"A company that has developed a game-changing technology to bridge the best of both the natural and the synthetic manufacturing benefits is InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF). Using an E. coli-based expression system, InMed has taken the lead by developing a biosynthesis process that uses cannabinoid DNA to create, in a controlled laboratory setting, compounds that are identical to those found in nature.\"The company is the world's first known company to utilize this biosynthesis manufacturing technique to create a biosynthetic cannabinoid for the treatment of glaucoma. Using this cannabinoid, InMed has formulated a hydrogel as a drug delivery mechanism for the eye condition. Normally, eyedrops are used to treat glaucoma through several applications a day. Conversely, the company's medicated hydrogel forms a film over the eye and only needs to be applied once, at bedtime, to stay in place all night. InMed's pharmaceutical-grade biosynthetic cannabinoids are identical to those found in nature and are more than 95% pure. They contain none of the mind-altering chemical in cannabis, tetrahydrocannabinol (THC), and are therefore free of any psychoactive properties.\"About InMed InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical...